氨酸甲基转移酶SMYD2和SMYD3:脏疾病中的新兴标
Xinyu Du1, Liyuan Yao1, Shougang Zhuang1,2
1Department of Nephrology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Kidney diseases (Basel, Switzerland)
|August 11, 2025
概括
含有SET和MYND域的蛋白2 (SMYD2) 和3 (SMYD3) 酶与脏疾病有关. 抑制SMYD2和SMYD3显示出治疗各种脏疾病的前景.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 含有SET和MYND域 (SMYD) 的蛋白质家族包括氨酸甲基转移酶,这对于通过蛋白质甲基化调节基因表达至关重要.
- SMYD 蛋白质具有 SET 和 MYND 域,这有助于它们的酶活性.
研究的目的:
- 审查SMYD2和SMYD3在病中的参与.
- 突出它们在脏疾病中的作用背后的机制.
- 为了强调它们对脏疾病的治疗潜力.
主要方法:
- 关于SMYD蛋白在病理学中的研究的文献综述.
- 对将SMYD2和SMYD3与癌症,多囊性病,纤维化和糖尿病病联系起来的研究分析.
- 检查SMYD2和SMYD3.3的药理和遗传抑制策略.
主要成果:
- 突变或SMYD2和SMYD3的过度表达与癌有关.
- 在各种病的动物模型中观察到SMYD2和SMYD3的表达和活性升高.
- 抑制SMYD2/SMYD3有效抑制脏瘤发生和囊的形成.
- 抑制SMYD2和SMYD3可以改善纤维化和糖尿病病模型的结果.
- 这些酶与急性损伤的发病有关.
结论:
- SMYD2和SMYD3在各种病的发展和进展中起着重要作用.
- 向SMYD2和SMYD3为治疗脏疾病提供了一个有前途的治疗策略.
- 对SMYD向疗法的进一步研究可能会导致脏病学患者改善的结果.
相关概念视频
01:28Chronic Kidney Disease III: Interprofessional Care
80
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
80
01:24Chronic Kidney Disease II: Clinical Manifestations
91
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
91